TIDMOXB

RNS Number : 7283N

Oxford Biomedica PLC

01 October 2021

Oxford Biomedica

Total Voting Rights

Oxford, UK - 01 October 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 30 September 2021 consisted of 86,083,845 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 86,083,845.

The above figure (86,083,845) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

 
 For further information, please contact: 
  Oxford Biomedica plc:                      Tel: +44 (0)1865 783 000 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R)), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAPEFELPFFEA

(END) Dow Jones Newswires

October 01, 2021 04:51 ET (08:51 GMT)

Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Oxford Biomedica
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Oxford Biomedica